ClinicalTrials.gg
CompletedNCT05868382Updated Dec 20, 2024Results posted

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

A Phase 2 interventional study of mRNA-1010 and mRNA-1010.4 in Influenza, sponsored by ModernaTX, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Enrollment
9th of 12
270 · median 471
Started
2023
with 1 other
Phase 2
2 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 2, and was the 9th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

The main purpose of the study is to evaluate the safety, reactogenicity, and the immunogenicity of mRNA-1010 vaccine candidate variations.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • mRNA-1010
  • Influenza Vaccine
  • Moderna
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Investigator has assessed that the participant understands and is willing and physically able to comply with protocol mandated follow up, including all procedures.
  • For assigned females at birth and of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.

Exclusion criteria

Exclusion Criteria:

  • Participant has had close contact with someone with laboratory-confirmed influenza infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu®) within the past 5 days prior to Day 1.
  • Participant is acutely ill or febrile (temperature ≥38.0℃elcius [100.4°Fahrenheit]) 72 hours prior to or at the Screening visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window.
  • Participant has a history of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
  • Reported history of congenital or acquired immunodeficiency, condition or immune-mediated disease, asplenia, or recurrent severe infections.
  • Participant has tested positive for influenza by local health authority-approved testing methods within 150 days prior to Day 1.
  • Reported history of anaphylaxis or severe reaction after receipt of mRNA vaccines or any components of the mRNA-1010 or influenza vaccines, including egg protein.
  • Participant has received systemic immunosuppressants for >14 days in total within 180 days prior to Day 1 (for , ≥10 mg/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. Inhaled, nasal and topical steroids are allowed. Intra-articular and epidural steroid injections are not allowed within 28 days before and/or after study intervention dosing.
  • Participant has received any vaccine authorized or approved by local health agency ≤28 days prior to study intervention dosing (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after study intervention dosing.
  • Participant has received a licensed seasonal influenza vaccine within 5 months (150 days) prior to Day 1.
  • Participant has participated in any seasonal influenza vaccine study within12 months prior to Day 1.
  • Participant is not aware whether they have received an influenza vaccine in the prior 12 months.
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to Day 1 or plans to donate blood products during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (actual)

Study arms

  • Experimental
    mRNA-1010 Dose C

    Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    mRNA-1010.4 Dose B

    Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.

    Biological: mRNA-1010.4

  • Experimental
    mRNA-1010.4 Dose C

    Participants will receive a single dose of mRNA-1010.4 by IM injection on Day 1.

    Biological: mRNA-1010.4

  • Experimental
    mRNA-1010.6 Dose A

    Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.

    Biological: mRNA-1010.6

  • Experimental
    mRNA-1010.6 Dose B

    Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.

    Biological: mRNA-1010.6

  • Experimental
    mRNA-1010.6 Dose C

    Participants will receive a single dose of mRNA-1010.6 by IM injection on Day 1.

    Biological: mRNA-1010.6

Interventions

  • BiologicalmRNA-1010

    Sterile liquid for injection

  • BiologicalmRNA-1010.4

    Sterile liquid for injection

  • BiologicalmRNA-1010.6

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: 7 days post-vaccination

  2. Number of Participants With Unsolicited Adverse Events (AEs)

    An unsolicited AE was an AE that was not solicited using a participant diary and that was communicated by a participant who has signed the informed consent. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.

    Time frame: Up to 28 days post-vaccination

  3. Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study or Treatment Discontinuation

    An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 181) are reported in this outcome measure.

    Time frame: Day 1 to Day 181 (end of study [EOS])

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B Strains

    Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation.

    Time frame: Days 1 (Baseline), 8, 29, 91, and 181

  2. Geometric Mean Fold Rise (GMFR) of Anti-HA Antibodies, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains

    The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% confidence interval (CI) for GMFR was calculated based on the t distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Baseline, Days 8, 29, 91, and 181

  3. Percentage of Participants With Seroresponse for mRNA-1010, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains

    Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroresponse was defined as (a) a post-vaccination antibody titer ≥ 4 \* lower limit of quantification (LLOQ) if baseline (Day 1) antibody titer was \< LLOQ or (b) a post-vaccination antibody titer ≥ 4-fold of baseline antibody titer if baseline antibody titer was ≥ LLOQ.

    Time frame: Days 8, 29, 91, and 181

07

Results

Posted Dec 20, 2024

Participant flow

Participant flow — Overall Study
MilestonemRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High Dose
Started603060303060
Received injection603060303060
Safety set603060303159
Solicited safety set603060303159
Per-protocol set552856292852
Completed543054262754
Not completed606436
Withdrew: Lost to follow-up506426
Withdrew: Withdrawal by subject100010

Outcome measures

PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
7 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsmRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High Dose
Any502753182555
Grade 1221111111215
Grade 224113251234
Grade 34510216
Grade 4000000
PrimaryNumber of Participants With Unsolicited Adverse Events (AEs)

An unsolicited AE was an AE that was not solicited using a participant diary and that was communicated by a participant who has signed the informed consent. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.

Time frame:
Up to 28 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsmRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High Dose
Number of Participants With Unsolicited Adverse Events (AEs)1149047
PrimaryNumber of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study or Treatment Discontinuation

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (Day 181) are reported in this outcome measure.

Time frame:
Day 1 to Day 181 (end of study [EOS])
Reported as:
Count of participants · Participants
Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study or Treatment Discontinuation
ParticipantsmRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High Dose
SAEs102101
AESIs000000
MAAEs14512238
AEs Leading to Study or Treatment Discontinuation000000
SecondaryGeometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B Strains

Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation.

Time frame:
Days 1 (Baseline), 8, 29, 91, and 181
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B Strains
titermRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High Dose
Influenza A H1N1 Antibody: Day 152.4 (41.5 to 66.2)60.9 (41.9 to 88.7)72.9 (53.9 to 98.5)78.2 (54.5 to 112.1)50.5 (34.2 to 74.6)48.2 (36.7 to 63.3)
Influenza A H1N1 Antibody: Day 8226.2 (164.8 to 310.6)272.4 (196.2 to 378.3)337.2 (244.9 to 464.3)240.2 (163.8 to 352.2)259.3 (166.9 to 403.0)331.3 (247.0 to 444.5)
Influenza A H1N1 Antibody: Day 29334.4 (247.8 to 451.2)316.1 (214.5 to 465.8)394.9 (299.1 to 521.5)255.0 (177.7 to 366.1)269.1 (184.5 to 392.5)349.0 (266.9 to 456.3)
Influenza A H1N1 Antibody: Day 91168.9 (125.2 to 227.8)202.4 (144.2 to 284.2)229.3 (174.4 to 301.4)160.0 (108.8 to 235.4)174.5 (117.0 to 260.3)179.6 (137.8 to 234.1)
Influenza A H1N1 Antibody: Day 181127.6 (95.9 to 169.7)164.1 (119.9 to 224.7)167.8 (122.4 to 230.0)119.9 (82.4 to 174.5)123.8 (88.2 to 173.8)137.4 (106.1 to 177.9)
Influenza A H3N2 Antibody: Day 133.3 (26.3 to 42.3)46.4 (31.6 to 68.1)41.2 (32.8 to 51.9)37.2 (26.7 to 51.9)29.7 (21.5 to 40.9)27.4 (21.8 to 34.4)
Influenza A H3N2 Antibody: Day 8125.6 (88.7 to 178.1)187.9 (128.2 to 275.5)188.4 (147.5 to 240.6)109.1 (71.4 to 166.6)125.0 (80.0 to 195.2)162.3 (118.2 to 222.8)
Influenza A H3N2 Antibody: Day 29159.0 (115.8 to 218.4)262.7 (170.9 to 403.8)248.2 (192.2 to 320.6)124.4 (78.2 to 198.1)136.2 (89.7 to 206.9)160.0 (118.7 to 215.7)
Influenza A H3N2 Antibody: Day 91105.1 (77.3 to 142.7)146.8 (101.4 to 212.6)154.8 (116.6 to 205.5)99.5 (69.8 to 141.9)94.0 (66.9 to 132.0)103.6 (80.0 to 134.0)
Influenza A H3N2 Antibody: Day 18187.8 (66.0 to 116.8)124.9 (84.6 to 184.2)107.9 (81.7 to 142.3)68.2 (46.4 to 100.4)67.7 (48.3 to 94.8)87.0 (65.2 to 116.2)
Influenza B/ Victoria Lineage: Day 163.4 (55.1 to 72.9)78.1 (60.5 to 100.9)82.5 (66.9 to 101.8)74.5 (59.4 to 93.4)64.0 (49.8 to 82.3)67.8 (58.2 to 78.9)
Influenza B/ Victoria Lineage: Day 888.9 (72.2 to 109.3)164.0 (119.5 to 225.1)194.7 (145.8 to 260.0)150.7 (112.2 to 202.4)129.6 (91.9 to 182.8)126.4 (100.7 to 158.7)
Influenza B/ Victoria Lineage: Day 2994.3 (75.4 to 117.8)174.5 (124.2 to 245.3)218.0 (160.3 to 296.5)132.2 (99.2 to 176.2)120.4 (90.3 to 160.6)132.8 (104.2 to 169.3)
Influenza B/ Victoria Lineage: Day 9189.2 (77.2 to 103.2)126.5 (100.9 to 158.5)138.2 (109.6 to 174.2)100.9 (78.2 to 130.1)84.1 (66.4 to 106.5)94.2 (80.8 to 109.7)
Influenza B/ Victoria Lineage: Day 18162.9 (53.7 to 73.7)75.2 (56.2 to 100.5)83.9 (68.5 to 102.7)59.9 (47.2 to 76.1)60.3 (49.7 to 73.2)60.2 (51.8 to 69.9)
Influenza B/ Yamagata Lineage: Day 171.9 (57.6 to 89.7)107.7 (72.3 to 160.4)96.3 (75.6 to 122.8)99.2 (70.0 to 140.5)77.1 (57.3 to 103.6)84.9 (67.4 to 106.9)
Influenza B/ Yamagata Lineage: Day 8181.2 (142.0 to 231.1)293.5 (195.8 to 440.0)305.7 (233.2 to 400.8)198.3 (141.9 to 277.3)215.5 (155.2 to 299.2)367.6 (280.4 to 481.8)
Influenza B/ Yamagata Lineage: Day 29181.5 (146.6 to 224.7)275.8 (187.5 to 405.8)336.2 (270.4 to 418.1)205.7 (142.4 to 297.0)187.9 (136.8 to 258.2)309.5 (246.8 to 388.1)
Influenza B/ Yamagata Lineage: Day 91134.1 (112.7 to 159.5)190.3 (140.0 to 258.7)218.9 (173.4 to 276.2)160.0 (120.1 to 213.2)141.4 (107.8 to 185.5)194.8 (161.7 to 234.7)
Influenza B/ Yamagata Lineage: Day 181109.4 (91.3 to 131.2)137.9 (101.0 to 188.3)140.6 (113.6 to 174.1)111.6 (79.5 to 156.4)125.4 (98.6 to 159.4)138.3 (114.3 to 167.4)
SecondaryGeometric Mean Fold Rise (GMFR) of Anti-HA Antibodies, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains

The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% confidence interval (CI) for GMFR was calculated based on the t distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Baseline, Days 8, 29, 91, and 181
Reported as:
Geometric mean · ratio
Geometric Mean Fold Rise (GMFR) of Anti-HA Antibodies, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains
ratiomRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High Dose
Influenza A H1N1 Antibody: Day 84.27 (3.13 to 5.783)4.47 (2.95 to 6.78)4.38 (3.18 to 6.04)3.07 (2.04 to 4.64)5.13 (3.40 to 7.75)6.87 (4.79 to 9.86)
Influenza A H1N1 Antibody: Day 296.38 (4.58 to 8.89)5.19 (3.37 to 7.99)5.42 (3.94 to 7.44)3.26 (2.15 to 4.95)5.32 (3.31 to 8.57)7.24 (5.16 to 10.17)
Influenza A H1N1 Antibody: Day 913.13 (2.36 to 4.17)3.32 (2.34 to 4.71)3.08 (2.24 to 4.25)2.05 (1.50 to 2.81)3.45 (1.94 to 6.13)3.71 (2.69 to 5.13)
Influenza A H1N1 Antibody: Day 1812.36 (1.80 to 3.10)2.69 (1.88 to 3.86)2.23 (1.61 to 3.08)1.59 (1.14 to 2.21)2.43 (1.43 to 4.12)2.87 (2.12 to 3.88)
Influenza A H3N2 Antibody: Day 83.82 (2.87 to 5.08)4.05 (3.03 to 5.42)4.44 (3.46 to 5.71)2.93 (2.05 to 4.19)4.21 (2.82 to 6.29)6.11 (4.65 to 8.02)
Influenza A H3N2 Antibody: Day 294.77 (3.74 to 6.09)5.66 (3.98 to 8.06)6.02 (4.68 to 7.75)3.34 (2.27 to 4.91)4.59 (3.08 to 6.83)5.85 (4.49 to 7.61)
Influenza A H3N2 Antibody: Day 913.11 (2.47 to 3.93)3.17 (2.20 to 4.55)3.79 (2.81 to 5.12)2.76 (1.91 to 3.99)3.17 (2.14 to 4.69)3.76 (3.05 to 4.65)
Influenza A H3N2 Antibody: Day 1812.59 (2.06 to 3.26)2.69 (2.01 to 3.61)2.66 (1.99 to 3.55)2.06 (1.43 to 2.97)2.25 (1.60 to 3.16)3.14 (2.47 to 4.00)
Influenza B/Victoria Lineage: Day 81.41 (1.20 to 1.65)2.10 (1.53 to 2.88)2.39 (1.93 to 3.00)2.02 (1.59 to 2.58)2.03 (1.62 to 2.52)1.90 (1.58 to 2.30)
Influenza B/Victoria Lineage: Day 291.49 (1.26 to 1.76)2.23 (1.65 to 3.03)2.64 (2.11 to 3.31)1.78 (1.40 to 2.26)1.88 (1.54 to 2.29)1.96 (1.61 to 2.38)
Influenza B/Victoria Lineage: Day 911.36 (1.16 to 1.59)1.62 (1.27 to 2.06)1.65 (1.38 to 1.97)1.34 (1.04 to 1.73)1.31 (1.04 to 1.66)1.39 (1.19 to 1.64)
Influenza B/Victoria Lineage: Day 1810.95 (0.79 to 1.15)0.96 (0.75 to 1.24)0.98 (0.81 to 1.19)0.74 (0.55 to 0.99)0.93 (0.74 to 1.15)0.89 (0.73 to 1.09)
Influenza B/Yamagata Lineage: Day 82.53 (2.02 to 3.17)2.73 (2.04 to 3.65)3.20 (2.42 to 4.23)2.00 (1.49 to 2.68)2.80 (2.07 to 3.78)4.32 (3.41 to 5.47)
Influenza B/Yamagata Lineage: Day 292.53 (2.04 to 3.12)2.56 (1.99 to 3.29)3.49 (2.72 to 4.48)2.07 (1.75 to 2.74)2.44 (1.75 to 3.39)3.65 (2.90 to 4.59)
Influenza B/Yamagata Lineage: Day 911.83 (1.54 to 2.17)1.77 (1.42 to 2.20)2.21 (1.78 to 2.74)1.59 (1.24 to 2.03)1.83 (1.37 to 2.46)2.29 (1.88 to 2.80)
Influenza B/Yamagata Lineage: Day 1811.47 (1.24 to 1.75)1.28 (0.97 to 1.69)1.41 (1.13 to 1.76)1.09 (0.84 to 1.42)1.61 (1.22 to 2.13)1.63 (1.34 to 1.97)
SecondaryPercentage of Participants With Seroresponse for mRNA-1010, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains

Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroresponse was defined as (a) a post-vaccination antibody titer ≥ 4 \* lower limit of quantification (LLOQ) if baseline (Day 1) antibody titer was \< LLOQ or (b) a post-vaccination antibody titer ≥ 4-fold of baseline antibody titer if baseline antibody titer was ≥ LLOQ.

Time frame:
Days 8, 29, 91, and 181
Reported as:
Number · percentage of participants
Percentage of Participants With Seroresponse for mRNA-1010, as Measured by HAI Assay for Vaccine-matched Influenza A and B Strains
percentage of participantsmRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High Dose
Influenza A H1N1 Antibody: Day 854.7 (40.4 to 68.4)50.0 (30.6 to 69.4)50.9 (36.8 to 64.9)31.0 (15.3 to 50.8)60.7 (40.6 to 78.5)70.0 (55.4 to 82.1)
Influenza A H1N1 Antibody: Day 2969.1 (55.2 to 80.9)53.6 (33.9 to 72.5)60.7 (46.8 to 73.5)41.4 (23.5 to 61.1)60.7 (40.6 to 78.5)69.2 (54.9 to 81.3)
Influenza A H1N1 Antibody: Day 9158.8 (44.2 to 72.4)50.0 (30.6 to 69.4)38.5 (25.3 to 53.0)29.6 (13.8 to 50.2)42.9 (24.5 to 62.8)51.0 (36.6 to 65.2)
Influenza A H1N1 Antibody: Day 18136.5 (23.6 to 51.0)39.3 (21.5 to 59.4)31.4 (19.1 to 45.9)16.7 (4.7 to 37.4)37.0 (19.4 to 57.6)42.0 (28.2 to 56.8)
Influenza A H3N2 Antibody: Day 854.7 (40.4 to 68.4)67.9 (47.6 to 84.1)56.6 (42.3 to 70.2)41.4 (23.5 to 61.1)57.1 (37.2 to 75.5)70.0 (55.4 to 82.1)
Influenza A H3N2 Antibody: Day 2965.5 (51.4 to 77.8)67.9 (47.6 to 84.1)73.2 (59.7 to 84.2)58.6 (38.9 to 76.5)64.3 (44.1 to 81.4)69.2 (54.9 to 81.3)
Influenza A H3N2 Antibody: Day 9154.9 (40.3 to 68.9)50.0 (30.6 to 69.4)57.7 (43.2 to 71.3)40.7 (22.4 to 61.2)60.7 (40.6 to 78.5)56.9 (42.2 to 70.7)
Influenza A H3N2 Antibody: Day 18142.3 (28.7 to 56.8)35.7 (18.6 to 55.9)45.1 (31.1 to 59.7)25.0 (9.8 to 46.7)37.0 (19.4 to 57.6)48.0 (33.7 to 62.6)
Influenza B/Victoria Lineage: Day 811.3 (4.3 to 23.0)17.9 (6.1 to 36.9)28.3 (16.8 to 42.3)20.7 (8.0 to 39.7)17.9 (6.1 to 36.9)18.0 (8.6 to 31.4)
Influenza B/Victoria Lineage: Day 2912.7 (5.3 to 24.5)25.0 (10.7 to 44.9)35.7 (23.4 to 49.6)17.2 (5.8 to 35.8)14.3 (4.0 to 32.7)19.2 (9.6 to 32.5)
Influenza B/Victoria Lineage: Day 913.9 (0.5 to 13.5)14.3 (4.0 to 32.7)17.3 (8.2 to 30.3)11.1 (2.4 to 29.2)3.6 (0.1 to 18.3)3.9 (0.5 to 13.5)
Influenza B/Victoria Lineage: Day 1815.8 (1.2 to 15.9)7.1 (0.9 to 23.5)3.9 (0.5 to 13.5)4.2 (0.1 to 21.1)0 (0.0 to 12.8)4.0 (0.5 to 13.7)
Influenza B/Yamagata Lineage: Day 835.8 (23.1 to 50.2)39.3 (21.5 to 59.4)39.6 (26.5 to 54.0)20.7 (8.0 to 39.7)28.6 (13.2 to 48.7)62.0 (47.2 to 75.3)
Influenza B/Yamagata Lineage: Day 2929.1 (17.6 to 42.9)32.1 (15.9 to 52.4)50.0 (36.3 to 63.7)27.6 (12.7 to 47.2)25.0 (10.7 to 44.9)53.8 (39.5 to 67.8)
Influenza B/Yamagata Lineage: Day 9117.6 (8.4 to 30.9)14.3 (4.0 to 32.7)26.9 (15.6 to 41.0)14.8 (4.2 to 33.7)21.4 (8.3 to 41.0)31.4 (19.1 to 45.9)
Influenza B/Yamagata Lineage: Day 18111.5 (4.4 to 23.4)10.7 (2.3 to 28.2)11.8 (4.4 to 23.9)4.2 (0.1 to 21.1)11.1 (2.4 to 29.2)16.0 (7.2 to 29.1)

Adverse events

Collected over Day 1 up to the end of study (Day 181). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mRNA-10100/60 (0%)1/60 (1.7%)0/60 (0%)
mRNA-1010.4 Low Dose0/30 (0%)0/30 (0%)0/30 (0%)
mRNA-1010.4 High Dose0/60 (0%)2/60 (3.3%)0/60 (0%)
mRNA-1010.6 Low Dose0/30 (0%)1/30 (3.3%)0/30 (0%)
mRNA-1010.6 Medium Dose0/31 (0%)0/31 (0%)0/31 (0%)
mRNA-1010.6 High Dose0/59 (0%)1/59 (1.7%)3/59 (5.1%)
Most frequent serious events
Most frequent serious events
EventmRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High Dose
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/600/300/601/300/310/59
PancreatitisGastrointestinal disorders0/600/300/600/300/311/59
CellulitisInfections and infestations0/600/301/600/300/310/59
Hypertensive emergencyVascular disorders0/600/301/600/300/310/59
OsteoarthritisMusculoskeletal and connective tissue disorders1/600/300/600/300/310/59
Most frequent other events
Most frequent other events
EventmRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High Dose
EcchymosisSkin and subcutaneous tissue disorders0/600/300/600/300/313/59

Baseline characteristics

Full Analysis Set included all randomized participants who received the study intervention.

Age, Continuous
Age, Continuous(years)mRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High DoseTotal
Mean34.5 ± 9.0836.7 ± 8.0634.6 ± 7.8736.7 ± 9.0535.9 ± 7.5633.8 ± 7.5435.0 ± 8.20
Sex: Female, Male
Sex: Female, Male(Participants)mRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High DoseTotal
Female341740131731152
Male261320171329118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)mRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High DoseTotal
Hispanic or Latino186257121987
Not Hispanic or Latino392433211840175
Unknown or Not Reported3022018
Race (NIH/OMB)
Race (NIH/OMB)(Participants)mRNA-1010mRNA-1010.4 Low DosemRNA-1010.4 High DosemRNA-1010.6 Low DosemRNA-1010.6 Medium DosemRNA-1010.6 High DoseTotal
American Indian or Alaska Native0001012
Asian22400210
Native Hawaiian or Other Pacific Islander0000000
Black or African American24121714101794
White291435141837147
More than one race4110118
Unknown or Not Reported1131129
08

Study locations

10 sites
  • CenExel RCA
    Hollywood, Florida 33024, United States
  • Suncoast Research Group
    Miami, Florida 33135, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • Rockville Internal Medicine
    Rockville, Maryland 20854, United States
  • DM Clinical Research
    Southfield, Michigan 48076, United States
  • Meridian Clinical Research
    Hastings, Nebraska 68901, United States
  • Meridian Clinical Research
    Lincoln, Nebraska 68510, United States
  • United Medical Associates
    Binghamton, New York 13905, United States
  • DM Clinical Research
    Sugar Land, Texas 77478, United States
  • Texas Center for Drug Development
    Tomball, Texas 77375, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Dec 2023, 7 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 7 months is close to that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2023
First posted
May 22, 2023
StartActual
May 15, 2023
Primary completionActual
Dec 19, 2023
CompletionActual
Dec 19, 2023
Results first posted
Dec 20, 2024
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05868382
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
May 22, 2023
Start date
May 15, 2023
Primary completion
Dec 19, 2023
Completion
Dec 19, 2023
Results posted
Dec 20, 2024
Last update
Dec 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1010 influenza vaccine

Start the discussion